Publication | Closed Access

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

OncologyMedicineMetronomic TherapyClinical TrialsGynecologyTopotecan Versus PlaceboPlatinum-resistant Ovarian CancerCancer TreatmentPharmacologyGynecology OncologyOvarian Cancer